Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation
Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
1 other identifier
interventional
145
1 country
7
Brief Summary
This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Apr 2010
Typical duration for phase_4
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
May 25, 2010
CompletedFirst Posted
Study publicly available on registry
June 3, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2012
CompletedSeptember 28, 2010
June 1, 2010
2.1 years
May 25, 2010
September 27, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Absence rate of IFDs assessed by physical examination and serum galactomannan test
during micafungin prophylaxis therapy and during 4 weeks after stopping of micafungin prophylaxis
Secondary Outcomes (2)
Survival rate
at day 100
Safety assessed by lab-test and adverse events
during micafungin prophylaxis therapy
Study Arms (1)
HSCT
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Patients will receive allogeneic hematopoietic stem cell transplantation
You may not qualify if:
- Aspartate transaminase or alanine transaminase level \> 5 times UNL
- Bilirubin \> 2. 5 times UNL
- History of allergy, sensitivity, or any serious reaction to an echinocandin
- Invasive fungal disease at the time of enrolment
- Systemic antifungal therapy within 72 hrs before administration of the first dose of study drug
- Positive pregnancy test
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Asan Medical Centerlead
- Astellas Pharma Korea, Inc.collaborator
Study Sites (7)
Unknown Facility
Busan, South Korea
Unknown Facility
Daegu, South Korea
Unknown Facility
Daejeon, South Korea
Unknown Facility
Goyang, South Korea
Unknown Facility
Hwasun, South Korea
Unknown Facility
Seoul, South Korea
Unknown Facility
Suwon, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Use Central Contact
Astellas Pharma Inc
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 25, 2010
First Posted
June 3, 2010
Study Start
April 1, 2010
Primary Completion
May 1, 2012
Study Completion
May 1, 2012
Last Updated
September 28, 2010
Record last verified: 2010-06